<DOC>
	<DOCNO>NCT00315211</DOCNO>
	<brief_summary>The purpose study : - To determine overall response rate patient treat least 2 cycle regimen . - To determine feasibility toxicity combination topotecan docetaxel .</brief_summary>
	<brief_title>Weekly Topotecan With Docetaxel Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Mediastinal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Recurred great 90 day initial treatment At least 1 measurable lesion Only 1 prior chemotherapy Must 18 year age ECOG performance status 0 2 Adequate hematologic , renal , hepatic function No prior use topotecan , docetaxel , irinotecan No symptomatic brain metastasis History cardiac arrhythmia , congestive heart failure , stroke , embolic event No prior investigational agent within 1 month prior Lung cancer mixed histology Known uncontrolled seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Small Cell Lung Cancer Recurrent</keyword>
</DOC>